As previously mentioned, agonists of the GLP-1R which avoid breakdown by DPP4 have been developed as means of treatment for type 2 diabetes and obesity to restore this effect (Nauck et al. 2004, Graaf et al. 2016, Chia & Egan 2020). Here, GLP1R is linked to obesity due to melanocortin 4 receptor deficiency.